- For Patients
- Introduction to the Marshall Protocol
- Length of the MP
- Immunopathology
- Managing immunopathology
- Food and drink
- Light restriction
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Starting the Marshall Protocol
- Resources for patients
- Marshall Protocol summary
- Palliative vs. curative treatments
- Patient interviews on Bacteriality
- Non-MP treatments
- Glossary
- The Protocol
- Marshall Protocol summary
- Publications and presentations
- Science behind immunopathology
- Science behind olmesartan (Benicar)
- Safety of olmesartan
- Resources for physicians
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Physicians' concerns about the MP
- Notice for emergency medical personnel
- The Pathogenesis
- Publications and presentations
- Science behind Marshall Pathogenesis
- Microbes in the human body
- Successive infection and variability in disease
- Autoimmune theory of disease
- Science behind vitamin D
- Metabolism of vitamin D and the VDR
- Th1 Spectrum Disorder - how chronic inflammatory diseases are related
- Transmission of bacteria and onset of chronic disease
- Evolutionary perspective on disease
- Incidence and prevalence of disease
- Evidence that chronic disease is caused by pathogens
- Diseases
- Foundation
- Related Sites
Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
| home:protocol:olmesartan [02.25.2019] – [Kidney disease] sallieq | home:protocol:olmesartan [06.01.2019] – [Related publications and presentations] sallieq | ||
|---|---|---|---|
| Line 123: | Line 123: | ||
| * inhibit liver fibrosis and aid liver healing(({{pubmed> | * inhibit liver fibrosis and aid liver healing(({{pubmed> | ||
| * reduce insulin resistance in rats(({{pubmed> | * reduce insulin resistance in rats(({{pubmed> | ||
| - | * 6 mg/kg olmesartan reduces the inflammatory process and bone loss in rats(({{pubmed> | + | * 6 mg/kg olmesartan reduces the inflammatory process and periodontal |
| * protect the mitochondria from age-associated damage from oxidation(({{pubmed> | * protect the mitochondria from age-associated damage from oxidation(({{pubmed> | ||
| * play a protective role against proliferative diabetic retinopathy (({{pubmed> | * play a protective role against proliferative diabetic retinopathy (({{pubmed> | ||
| Line 200: | Line 201: | ||
| - | {{tag> | + | {{tag> |
| ===== Notes and comments ===== | ===== Notes and comments ===== | ||
home/protocol/olmesartan.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.